We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Polydone is a project management platform to help tech companies plan and manage tasks, projects and people. The platform is easy to use and uses automation, artificial intelligence and machine learning to help businesses plan timelines and obtain accurate estimates - helping businesses to avoid human error by 90%. Polydone currently caters for tech companies of up to 50 people but will be expanding to other sectors and larger teams in the future. 
days to go: Expired investment: £128,106
A web-based location experience platform for businesses to market their content for their target audience by users visiting physical locations to view digital content. Landmrk's service is currently used by travel, entertainment and retail industries and allows businesses to provide 'rewards' when customers reach the location. Revenue is primarily generated from marketing agencies and businesses licensing the platform on a monthly, quartely or annual basis.
days to go: Expired investment: £519,364
LawBite keeps small companies safe and sound at a price they can afford. Through its Platform it provides plain English legal documents and its own suite of software tools for editing, sharing, e-signing and storage. Wrapped around its Platform it provides a virtual law firm so that SME’s can speedily get affordable, understandable advice. LawBite doesn't carry expensive overhead or a Partnership structure, so it normally costs 50% or less than conventional law firms. However, LawBite is regulated by the Solicitors Regulation Authority, carries £3 million of indemnity insurance and only uses experienced solicitors and barristers. So the only short-cut customers take is in relation to price.
days to go: Expired investment: £3,001
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button. 
days to go: Expired investment: £1,406,667
DiPocket has created a mobile banking app to make instant international bank transfers, with low foreign exchange rates quick and easy. The app is a simple solution to collect and spend money with friends, and it comes with a range of mastercards so it can be used anywhere.
days to go: Expired investment: £157,275
PlusGuidance is an online counselling/therapy platform that gives people immediate access to counselling. It provides secure video, voice, IM and email sessions directly through the site, and booking in-person sessions too. Our Mission - Immediate access to counselling for everyone.Business Model - Software-as-a-Service for counsellors, who pay a monthly fee to use secure online sessions, practice management tools to manage their clients, and a public web profile in our directory.
days to go: Expired investment: £115,022
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph